Send to

Choose Destination
Toxins (Basel). 2011 Aug;3(8):1004-19. doi: 10.3390/toxins3081004. Epub 2011 Aug 15.

Monoclonal antibody therapies against anthrax.

Author information

Laboratory of Infectious Diseases National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.


Anthrax is a highly lethal infectious disease caused by the spore-forming bacterium Bacillus anthracis. It not only causes natural infection in humans but also poses a great threat as an emerging bioterror agent. The lethality of anthrax is primarily attributed to the two major virulence factors: toxins and capsule. An extensive effort has been made to generate therapeutically useful monoclonal antibodies to each of the virulence components: protective antigen (PA), lethal factor (LF) and edema factor (EF), and the capsule of B. anthracis. This review summarizes the current status of anti-anthrax mAb development and argues for the potential therapeutic advantage of a cocktail of mAbs that recognize different epitopes or different virulence factors.


Bacillus anthracis; a cocktail of mAbs; anti-EF mAbs; anti-LF mAbs; anti-PA mAbs; anti-capsule mAbs; post-exposure treatment of anthrax

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center